KR20140032944A - 항폴레이트 수용체 알파 항체 당형태 - Google Patents

항폴레이트 수용체 알파 항체 당형태 Download PDF

Info

Publication number
KR20140032944A
KR20140032944A KR1020137012669A KR20137012669A KR20140032944A KR 20140032944 A KR20140032944 A KR 20140032944A KR 1020137012669 A KR1020137012669 A KR 1020137012669A KR 20137012669 A KR20137012669 A KR 20137012669A KR 20140032944 A KR20140032944 A KR 20140032944A
Authority
KR
South Korea
Prior art keywords
fra
amino acid
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137012669A
Other languages
English (en)
Korean (ko)
Inventor
필립 엠. 사스
니콜라스 니콜라이데스
루이기 그라쏘
에릭 루티어
웨이 구
제이슨 영
준 야오
Original Assignee
모르포테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포테크, 인크. filed Critical 모르포테크, 인크.
Publication of KR20140032944A publication Critical patent/KR20140032944A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020137012669A 2010-10-20 2011-10-19 항폴레이트 수용체 알파 항체 당형태 Withdrawn KR20140032944A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39481210P 2010-10-20 2010-10-20
US61/394,812 2010-10-20
PCT/US2011/056966 WO2012054654A2 (en) 2010-10-20 2011-10-19 Anti-folate receptor alpha antibody glycoforms

Publications (1)

Publication Number Publication Date
KR20140032944A true KR20140032944A (ko) 2014-03-17

Family

ID=45975873

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137012669A Withdrawn KR20140032944A (ko) 2010-10-20 2011-10-19 항폴레이트 수용체 알파 항체 당형태

Country Status (12)

Country Link
US (1) US20120164137A1 (cg-RX-API-DMAC7.html)
EP (1) EP2629798A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014505012A (cg-RX-API-DMAC7.html)
KR (1) KR20140032944A (cg-RX-API-DMAC7.html)
CN (1) CN103347537A (cg-RX-API-DMAC7.html)
AU (2) AU2011317088B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013009275A2 (cg-RX-API-DMAC7.html)
CA (1) CA2815080A1 (cg-RX-API-DMAC7.html)
IL (1) IL225579A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013004202A (cg-RX-API-DMAC7.html)
RU (1) RU2013122843A (cg-RX-API-DMAC7.html)
WO (1) WO2012054654A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
JP6122948B2 (ja) 2012-05-15 2017-04-26 モルフォテック, インコーポレイテッド 胃癌の治療のための方法
SG11201500938XA (en) * 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
CN104884617B (zh) 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) * 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
EP2871190A1 (en) * 2013-11-11 2015-05-13 ATLAB Pharma Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity
ES2808853T3 (es) 2014-11-20 2021-03-02 Hoffmann La Roche Cadenas ligeras comunes y procedimientos de uso
RS61010B1 (sr) 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
CA2969225C (en) * 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
CN122075735A (zh) 2015-09-17 2026-05-26 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
EP3765521A4 (en) 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
KR102275930B1 (ko) * 2018-03-14 2021-07-12 (주)알테오젠 Folr1에 특이적으로 결합하는 항체 및 그의 용도
CN118344485B (zh) * 2024-06-18 2024-10-15 南京欧凯生物科技有限公司 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054048A1 (en) * 2003-07-29 2005-03-10 Luigi Grasso Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
BRPI0514068B8 (pt) * 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CN101374545B (zh) * 2005-04-15 2012-03-28 免疫基因公司 消除肿瘤中的异质或混合细胞群体
EP2172487A1 (en) * 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
WO2011116387A1 (en) * 2010-03-19 2011-09-22 Tetragenetics, Inc. Production of aglycosylated monoclonal antibodies in ciliates

Also Published As

Publication number Publication date
WO2012054654A3 (en) 2012-08-02
CN103347537A (zh) 2013-10-09
AU2011317088A1 (en) 2013-05-02
MX2013004202A (es) 2013-10-17
US20120164137A1 (en) 2012-06-28
EP2629798A2 (en) 2013-08-28
AU2011317088B2 (en) 2016-01-21
RU2013122843A (ru) 2014-11-27
CA2815080A1 (en) 2012-04-26
AU2016202082A1 (en) 2016-04-28
JP2014505012A (ja) 2014-02-27
BR112013009275A2 (pt) 2017-06-20
WO2012054654A2 (en) 2012-04-26
EP2629798A4 (en) 2014-05-28
IL225579A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CN108650886B (zh) 多价和多特异性gitr-结合融合蛋白
CN107148430B (zh) 抗tigit抗体
EP3356532B1 (en) Agonistic antibodies specifically binding human cd40 and methods of use
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
CA2556027C (en) Monoclonal antibodies that specifically block biological activity of a tumor antigen
AU2011317088B2 (en) Anti-folate receptor alpha antibody glycoforms
CN112424358B (zh) 与细胞粘附分子3结合的抗体
KR102921110B1 (ko) 항체-약물 접합체 및 이의 용도
TW200817436A (en) Antigen binding molecules that bind EGRF, vectors encoding same, and uses thereof
KR20190042037A (ko) 항-tim-3 항체 및 그의 용도
KR20190028534A (ko) 항 gprc5d 항체, gprc5d 및 cd3에 결합하는 이중특이성 항원 결합 분자, 및 이들의 용도
KR20160067978A (ko) Vegf 길항제와 항-ctla-4 항체의 조합물을 포함하는 조성물 및 방법
WO2021023108A1 (zh) 一种抗pd-1抗体及其医药用途
EP4674868A1 (en) Fap/4-1bb/cd40 binding molecule and medicinal use thereof
CN114057877A (zh) 抗pd-l1抗体及其应用
KR102916382B1 (ko) 항-cldn-18.2 항체 및 그 용도
TW202330027A (zh) 抗cd-47抗體製劑
KR20230154981A (ko) 항-인간 cxcr5 항체 및 이의 용도
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
HK40069234A (en) Anti -pd-l1 antibody and use thereof
HK40047612A (en) Antibody binding to cell adhesion molecule 3
HK40055449A (en) Novel anti-cd4 antibodies
HK40048585A (en) Anti-her2/pd1 bispecific antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid